> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Draft Guide on Generic Rifaximin Bioequivalence
- URL: https://www.fdaweb.com/draft-guide-on-generic-rifaximin-bioequivalence/
- Published: 2017-03-17T12:00:00.000Z
- Updated: 2026-09-14T22:12:18.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5138228

*Federal Register* notice: FDA has made available a revised draft guidance for industry on generic rifaximin oral tablets and bioequivalence issues. The “Draft Guidance on Rifaximin” is intended to provide product-specific recommendations on, among other things, the design of bioequivalence studies to support ANDAs for rifaximin oral tablets. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2017-03-16/pdf/2017-05245.pdf?ref=fdaweb.com).